Top Research Reports for Meta Platforms, Palantir & Abbott

Friday, June 20, 2025

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Palantir Technologies Inc. (PLTR) and Abbott Laboratories (ABT), as well as two micro-cap stocks SandRidge Energy, Inc. (SD) and CompX International Inc. (CIX). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.

These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Ahead of Wall Street

The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.

You can read today's AWS here >>> Pre-Markets Climb on Rate Cut Visibility

Today's Featured Research Reports

Meta Platforms’ shares have outperformed the Zacks Internet - Software industry over the past year (+39.2% vs. +37.1%). The company is benefiting from steady user growth across all regions, particularly Asia Pacific. Increased engagement for its offerings like Instagram, WhatsApp, Messenger and Facebook has been a major growth driver. 

META has been leveraging AI to improve the potency of its offerings. These services currently reach more than 3.43 billion people daily. Meta Platforms’ growing footprint among young adults, driven by improving recommendations, boosts its competitive prowess. AI usage is making it a popular name among advertisers. This is expected to drive top-line growth. 

Meta Platforms now expects to invest significantly more over the next few years in developing more advanced models and the largest AI services in the world. However, monetization of these AI services will take considerable time, which is a concern.

(You can read the full research report on Meta Platforms here >>>)

Shares of Palantir have outperformed the Zacks Internet - Software industry over the year-to-date period (+85% vs. +13%). The company’s AI strategy, driven by Foundry, Gotham and AIP platforms, targets government and commercial sectors, enabling real-time insights and operational efficiency. 

Notable defense projects like Open DAGIR, and AIP boot camps for commercial clients boost customer acquisition. With $5.2 billion in cash, no debt and S&P 500 inclusion, Palantir enjoys strong liquidity, growing revenues and increased investor visibility. 

However, PLTR's reluctance to pay quarterly dividends is a minus for dividend-seeking investors. Intense competition from tech giants and rising costs amidst a rapidly evolving AI landscape and an elevated valuation also challenge its appeal. 

(You can read the full research report on Palantir here >>>)

Abbott’s shares have outperformed the Zacks Medical - Products industry over the past year (+27.8% vs. +8.9%). The company’s pipeline is unlocking new growth opportunities, supporting the company’s positive momentum and strong growth outlook for 2025. Freestyle Libre, Lingo and Libre Rio CGM devices are on a great trajectory.

Alinity, the company’s next-generation suite of systems, is a key driver in the core lab diagnostics business. Abbott is optimistic about its latest progress with biosimilars and expects this to significantly boost EPD sales, beginning 2025. 

Within Nutrition, despite softness in international pediatric arm, Abbott is regaining market share banking on strong Adult Nutrition business. Yet, the significant runoff of COVID-19 testing-related sales is hurting Abbott’s Diagnostics growth. Headwinds such as tough macro conditions and foreign exchange also adds to the worry. 

(You can read the full research report on Abbott here >>>)

Shares of SandRidge Energy have outperformed the Zacks Oil and Gas - Integrated - U.S. industry over the year-to-date period (+5.3% vs. -1.6%). This microcap company with a market capitalization of $443.18 million has a debt-free balance sheet and $101.1 million cash position back strong self-funding capacity, and $13.6 million in free cash flow in Q1 2025. 

Adjusted EBITDA jumped 73% to $25.5 million on higher volumes and better gas prices, with gas now 49% of production. Since 2023, $158 million has been returned to shareholders via dividends and buybacks, with $70 million repurchase capacity remaining. Cherokee drilling supports reserve growth, but capital intensity and WTI/gas price volatility pose risks. 

Heavy back-half completions, cost inflation, and natural gas legacy underutilization limit efficiency. Large NOLs support tax sheltering but rely on consistent profits; Section 382 limits apply. Reserve quality hinges on Cherokee execution as legacy reserves decline. Commodity swings and execution missteps could pressure cash flow and returns despite strong capital discipline.

(You can read the full research report on SandRidge Energy here >>>)

CompX International’s shares have outperformed the Zacks Office Supplies industry over the past year (+18.8% vs. -38%). This microcap company with a market capitalization of $293.43 million has first-quarter 2025 results highlight resilient core operations and expanding profitability. Security Products maintained a stable gross margin (29.8%) despite OEM softness, supported by gains in government and healthcare markets. 

Marine Components delivered a 24% year-over-year sales increase and a structural margin uplift to 22.3%, driven by fixed cost leverage and a favorable product mix. The company-wide gross margin rose to 30.2%, fueling a 58% surge in operating income. Cash remained strong at $56.1 million, with no debt and improved inventory efficiency. 

However, risks include negative operating cash flow due to rising receivables, a 29% drop in interest income and tariff-driven raw material inflation. Continued OEM channel weakness and DSO expansion raise caution, but internal execution and margin tailwinds position CompX for an upside in 2025.

(You can read the full research report on CompX International here >>>)

Other noteworthy reports we are featuring today include Intuit Inc. (INTU), Illinois Tool Works Inc. (ITW) and Veeva Systems Inc. (VEEV).

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

Expanding AI Usage Drives Meta Platforms' (META) Prospects

Modular Sales Tactic Aids Palantir (PLTR), Competition High

Solid EPD Prospects, CGM Leadership Boosts Abbott (ABT)

Featured Reports

Food Equipment Unit Aids Illinois Tool (ITW) Amid Forex Woes
Per the Zacks analyst, Illinois Tool is benefitting from its Food Equipment unit, driven by strength in the institutional end markets in North America. However, forex woes are an added concern.

Ross' (ROST) Strong Demand Trends Aid Sales, Tariff Woes Hurt
Per the Zacks analyst, Ross Stores' sales benefits from ongoing strength in consumer demand. But ongoing macroeconomic and geopolitical uncertainty, including tariff woes, raise investor concerns.

Investments Aids PG&E Corporation (PCG) Amid Poor Solvency
Per the Zacks analyst, PG&E makes systematic investments to maintain and upgrade the reliability of its infrastructure. Yet its poor financial ratios indicate weak solvency position.

Woodward (WWD) Boosted by Aerospace & Industrial Strength
Per the Zacks analyst, Woodward's strong Aerospace and Core Industrial units are driving growth, amid challenges from China's on-highway natural-gas truck market and Aerospace supply-chain issues.

Season Pass Aids Vail Resorts (MTN) Amid Weak Visitation
Per the Zacks analyst, Vail Resorts benefits from a stable season pass program and offerings such as the Epic Pass, Epic Day Pass, and Epic Australia Pass. However, weak visitation is a concern.

AUM Growth Aids Main Street (MAIN), Rising Costs a Drag
Per the Zacks analyst, Main Street's robust asset under management (AUM) and strong liquidity back growth. However, increased expenses due to expansion may hurt profitability.

Immunovant Bets on IMVT-1402 Amid Intense Competition
Per the Zacks Analyst, IMVT-1402 could become a best-in-class medication for several autoimmune indications. However, significant competition in the market remains a worry.

New Upgrades

Intuit (INTU) Rides on Product Refresh, Higher Subscriptions
Per the Zacks analyst, Intuit is benefiting from frequent product refreshes, which help it to gain customers. Moreover, increase in subscriptions is driving stable revenue growth for the company.

Veeva Systems (VEEV) Gains on Solid R&D, Strategic Alliances
Per the Zacks analyst, Veeva Systems is gaining from strong customer adoption and strategic alliances. Innovation, a solid product portfolio, and a debt-free balance sheet are also fueling growth.

Increase in New Insurance Written Aid MGIC Investment (MTG)
Per the Zacks analyst, MGIC Investment is poised to grow on higher insurance in force, improved direct premium yield, higher annual persistency, lower claims and a strong capital position.

New Downgrades

Helmerich & Payne (HP) Risks from Falling U.S. Rig Demand
The Zacks analyst believes that Helmerich & Payne's strong dependence on U.S. drilling puts it at risk of lower rig demand and weaker margins if oil prices continue falling.

Campbell's (CPB) Appears Troubled by Elevated Cost Inflation
Per the Zacks analyst, cost inflation hurt Campbell's gross margin. In Q3 adjusted gross profit margin fell 110 basis points to 30.1%, impacted by cost inflation and supply-chain costs among others.

Soft Industrial Demand, Repositioning Ail Ingevity (NGVT)
According to the Zacks analyst, Ingevity faces headwinds from weaker industrial demand. Its repositioning measures will also hurt sales in the industrial specialties product line.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research